Is CJC-1295 / Ipamorelin legal in Australia?

These compounds are not ARTG-registered medicines. An unapproved classification is not permission for sale or human use, and exceptional-access requirements do not override other restrictions.

Why are CJC-1295 and Ipamorelin blended together?

They are discussed together because they target different parts of growth-hormone signalling. That rationale does not establish that a blend is effective or safe for human use.

What safety and evidence questions need assessment?

Relevant questions include the quality of human studies, possible interactions, medical conditions that affect risk and gaps in long-term safety information.

Regulatory status

CJC-1295 + Ipamorelin in Australia: Legal Status & Evidence

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Overview

CJC-1295 and Ipamorelin are distinct experimental compounds studied in relation to growth-hormone signalling. Studies of either compound alone do not establish the safety or clinical usefulness of a combined product.

Indications reviewed at consultation

Medical history, allergies and previous treatment
Current medicines and potential interactions
Pregnancy, breastfeeding and relevant health conditions
Evidence limitations and appropriate alternatives

Administration

A combined CJC-1295 and Ipamorelin product cannot be assessed by assuming that findings about either compound apply to the blend.

Cautions

Not for use in pregnancy, breastfeeding, active cancer, or uncontrolled diabetes. Requires baseline pathology review and prescriber follow-up.

Frequently asked questions

Is CJC-1295 / Ipamorelin legal in Australia?: These compounds are not ARTG-registered medicines. An unapproved classification is not permission for sale or human use, and exceptional-access requirements do not override other restrictions.
Why are CJC-1295 and Ipamorelin blended together?: They are discussed together because they target different parts of growth-hormone signalling. That rationale does not establish that a blend is effective or safe for human use.
What safety and evidence questions need assessment?: Relevant questions include the quality of human studies, possible interactions, medical conditions that affect risk and gaps in long-term safety information.

Educational content only. Whether any treatment is appropriate, and whether it can lawfully be supplied in Australia, is a decision for a registered doctor and the TGA.

General information only, not medical advice. The treating doctor decides whether any treatment is appropriate.

Important information

Official sources — regulatory context

These sources explain medicine regulation, access and health advertising requirements; they do not endorse this site. An educational disclaimer does not establish compliance or replace advice from a registered clinician.

Related peptides

Unapproved peptide

BPC-157

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

Ipamorelin

Research findings do not establish an individual clinical benefit. Evidence limitations, adverse effects and Australian regulatory status require careful assessment.

Regulatory status

AOD-9604

Evidence limitations and individual safety require clinical assessment. Registration and lawful supply must be checked; this information is not a treatment recommendation.

GLP-1 / GIP weight management

Tirzepatide

Dual GIP and GLP-1 receptor agonist; registered prescription products only.

Australian consultation information by city

Questions about your options?

Learn how a telehealth consultation with an AHPRA-registered Australian doctor works. Whether any treatment is appropriate is a decision your doctor makes based on your individual clinical needs.

How Australian access pathways work